247 related articles for article (PubMed ID: 12014682)
1. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
2. Human ovarian tumors express gamma-glutamyl transpeptidase.
Hanigan MH; Frierson HF; Brown JE; Lovell MA; Taylor PT
Cancer Res; 1994 Jan; 54(1):286-90. PubMed ID: 7903206
[TBL] [Abstract][Full Text] [Related]
3. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages.
Klimp AH; Hollema H; Kempinga C; van der Zee AG; de Vries EG; Daemen T
Cancer Res; 2001 Oct; 61(19):7305-9. PubMed ID: 11585770
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
5. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
Kuwata T; Kitagawa M; Takemura T; Hirokawa K
Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
[TBL] [Abstract][Full Text] [Related]
6. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer.
Katso RM; Manek S; Biddolph S; Whittaker R; Charnock MF; Wells M; Ganesan TS
Cancer Res; 1999 May; 59(10):2265-70. PubMed ID: 10344726
[TBL] [Abstract][Full Text] [Related]
9. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
10. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
Hu YQ; Liu YJ
Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
[TBL] [Abstract][Full Text] [Related]
11. Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer.
Amsterdam A; Shezen E; Raanan C; Schreiber L; Prus D; Slilat Y; Ben-Arie A; Seger R
Int J Oncol; 2011 Sep; 39(3):649-56. PubMed ID: 21687944
[TBL] [Abstract][Full Text] [Related]
12. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
15. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase 2 expression in serous tumors of the ovary.
Singhal PK; Spiegel G; Driscoll D; Odunsi K; Lele S; Rodabaugh KJ
Int J Gynecol Pathol; 2005 Jan; 24(1):62-6. PubMed ID: 15626918
[TBL] [Abstract][Full Text] [Related]
18. [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
Zhang WY; Pan Y; Zhu LR; Zhang JZ; Zhang M; Feng K; Zhou L; Yu L; Zhang XM; Ng SW
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(42):2988-91. PubMed ID: 16324386
[TBL] [Abstract][Full Text] [Related]
19. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
20. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
